Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait
Sponsor: Novartis Pharmaceuticals
Summary
The aim of this study is to assess demographics, clinical features, treatment patterns, and the comorbidity burden and its impact on CML patients in the real-world clinical setting in Kuwait. Adult patients with Philadelphia positive-chromosome (Ph+ve) CML who have received at least one line of tyrosine kinase inhibitor (TKI) treatment, such as but not limited to imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib will be included. The study will use data from the hospital records of CML patients between January 2014 and January 2024.
Official title: Retrospective Study on Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia (CML) in Kuwait
Key Details
Gender
All
Age Range
21 Years - 90 Years
Study Type
OBSERVATIONAL
Enrollment
400
Start Date
2026-05-16
Completion Date
2026-09-19
Last Updated
2026-03-31
Healthy Volunteers
No